Leerink Partners analyst Joseph Schwartz maintained a Buy rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) on Monday, setting a price target of $178, which is approximately 108.31% above the present share price of $85.45.
Schwartz expects Ultragenyx Pharmaceutical to post earnings per share (EPS) of $0.00 for the third quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Moderate Buy rating of shares in Ultragenyx Pharmaceutical, with an average price target of $145.25.
The analysts price targets range from a high of $178 to a low of $91.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $86.98 million and a net profit of -$82.78 million. The company's market cap is $5.8 billion.
According to TipRanks.com, Leerink Partners analyst Joseph Schwartz is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 10.2% and a 44.10% success rate.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.